semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HER2-positive Breast Cancer ≥18 years old with histologically confirmed HER2 positive breast cancer. 2. Documented HER2 overexpression by local laboratory ,defined as immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) positive. 3. Physician has determined that treatment with pyrotinib is indicated. 4. Traceable medical record available  Patients who are unable to understand the nature of the study and are unwilling to sign an informed consent . 2. Pregnant or breast feeding patients 3. Patients participating in any interventional clinical trial that includes investigational or marketed products at the time of enrollment. 4. Patients not suitable for this study under investigators' consideration
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Nasopharyngeal Carcinoma Histological diagnosis of nasopharyngeal carcinoma Stage III or IVA according to UICC/AJCC 8th staging system Age ≥18 No prior anti-tumor treatment Karnofsky Performance Score (KPS)≥70 Adequate blood supply Informed consent obtained  Can not take contrast-MRI imaging Pregnant Combined with other malignant tumor (except basal cell carcinoma of skin)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency Women British African-Caribbean Self-reported Having African ancestral origin and migrated via the Caribbean islands, or having at least one parent with African ancestral origin that migrated via the Caribbean Living in England for >2 months Aged 18-35 or >55 years No significant health issues Pre-menopausal (regular menstrual periods) or Post-menopausal (menstrual periods stopped for longer than 12 consecutive months) BMI 18-30kg/m2  Women in perimenopause or menopause Pregnant or planning pregnancy during study period Hypercalcaemia (>2.5mmol/L) assessed and excluded at baseline Currently receiving treatment for medical conditions that are likely to affect vitamin D metabolism (osteoporosis, hormone replacement therapy, anti-estrogens treatment, antiepileptic drugs and breast cancer treatment) Regular use of sun beds Having a sun holiday one month prior to commencing study or plans for a sun holiday for more than 4 weeks within the study period Women who take vitamin D or calcium supplements (or multivitamin supplements that contain these vitamins) If potential participant agrees to stop supplement use to join the study, a wash-out period of 8 weeks prior to commencing the study is acceptable Living in England for less than 2 months
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Triple Negative Breast Cancer HER2-positive Breast Cancer Sentinel Lymph Node Women, aged ≥ 18 years Invasive HER2+ (HR+/-) or TN breast cancer Primary tumor (T), clinical stage T1-3 Neoadjuvant systemic therapy (NST), at least 3 cycles Tumor stage assessed with breast MRI before start NST Clinically node-negative before start NST (no suspect ALNs on ultrasound and FGD-PET/CT, or negative cyto-/histopathology in case of suspect nodes) MRI after or during NST shows radiologic complete response Written and signed informed consent  Primary tumor (T) clinical stage T4 Patients without ultrasound or FDG-PET/CT pre-NST History of breast cancer ipsilateral breast Synchronous contralateral breast cancer Synchronous M1 disease
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer WHO performance status 0-1 Invasive Breast Cancer with cT1-3 cN1-2 at time of diagnosis Axillary nodal involvement can be detected using, clinical examination, ultrasound, CT scan or PET scan Pathologic confirmation using, FNAC, core biopsy or excisional biopsy ER, PR, Her2 neu and Ki67 status should be available for all patients All patients should have received standard preoperative chemotherapy prior to surgery At the time of surgery, all patients should have axillary clearance with at least 6 nodes harvested from the axilla Patients who have undergone mastectomy or lumpectomy with negative margins with ypN0, ypN0(+i) or ypN0(+mol) are eligible for randomization  Poor performance status Definitive clinical or radiologic evidence of metastatic disease T4 tumors including inflammatory breast cancer N3 disease detected clinically or by imaging Patients with histologically positive axillary nodes after preoperative chemotherapy Positive surgical margin after definitive surgery Previous ipsilateral or contralateral breast cancer Previous chest wall or breast irradiation Second primary cancer Active connective tissue disease
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female Female Age 18 years or older Invasive ductal breast carcinoma and ductal carcinoma in situ having undergone breast conservation surgery May neo-adjuvant treated subjects (chemotherapeutic, endocrine therapy, or radiation) Ability to understand and the willingness to sign a written informed consent document  Metastatic cancer (Stage IV) Lobular carcinoma as primary diagnosis
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasm Female Sample selection 1. Prior information of the patient. 2. Histologically proven invasive breast cancer, 3. ER-positive breast cancer, according to the following ER ≥10 % (local assessment) 4. HER2-negative tumor by IHC (score 0 or 1+) and/or fluorescent in situ hybridization (FISH)/chromogenic in situ hybridization (CISH) negative (local assessment) 5. IHC staining slides for ER, PR, KI67 and HER2 carry out on surgical resection according to local protocol available, 6. In situ hybridization (ISH) staining for HER2 carry out on surgical resection, in case of IHC 2+ for HER2 immunostaining 7. EndoPredict test results available (EPclin), 8. Formalin-fixed and paraffin-embedded (FFPE) block from surgical resection of the primary tumor available, 9. Patient ≥18 years old
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Women with histological confirmed ER/PR positive, HER2-negative MBC Age >18 years old Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC Adequate hematologic, renal and hepatic function Signed informed consent (ICF)  Active malignancy other than MBC Active infection
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Breast Cancer HER2 Preoperative Systemic Treatment HER2 positive 2. early invasive breast cancer (cT1-3N0-1M0) 3. using one-year trastuzumab as anti-HER2 treatment  metastasis and recurrent breast cancer 2. using trastuzumab less than a year
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Blood Pressure Hypertension Cancer Cancer, Breast Cancer of Prostate Cancer Colorectal Cancer, Endometrial Cancer of Head and Neck Non Small Cell Lung Cancer CVD - Cardiovascular Disease Diabetes Mellitus Hypercholesterolemia Diabetes A total of 800 individuals who fall under the following will be enrolled Diagnosed with any of the following selected solid tumors - Stage I-III breast [female], colorectal, endometrial, head/neck [H/N], and prostate cancer Stage I-II non-small cell lung cancer [NSCLC] Treated with curative intent 79 years old Has at least one of three CVD comorbidities (hypertension, diabetes, or hypercholesterolemia) based upon whether the patient is currently on a medication for the comorbidity at time of recruitment Had a visit with their PCP in the previous 12 months  Individuals with a history of the following conditions will be ineligible Myocardial infarction in the previous 24 months Stage III-IV heart failure Stage III-IV chronic kidney disease
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  HER2-positive Breast Cancer Chemotherapy Effect Circulating Tumor DNA HER2+ Breast cancer Stage IIA IIIC Plan to receive neoadjuvant chemotherapy with docetaxel, carboplatin, herceptin, perjeta Sign to informed consent  Double primary cancer
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Medication Administered in Error English or Spanish-speaking 2. 18 years of age and older 3. Child discharged home with a Rx for >1 daily liquid medication (other than multivitamin) 4. Primary person who will administers child's medications. 5. Willingness and ability to participate  Does not have a working phone number 2. Does not have access to internet (via computer/smartphone) 3. Does not have a mobile phone that receives texts. 4. Not able to return to the hospital for their child's follow-up visit 5. Visual acuity worse than 20/50 according to the Rosenbaum Pocket Screener 6. Uncorrectable hearing impairment
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-22.0,  Acute Myeloid Leukemia All patients must be enrolled on APEC14B1 and consented to Screening (Part A) prior to enrollment and treatment on AAML1831. Submission of diagnostic specimens must be done according to the Manual of Procedures). Risk stratification will not be possible without the submission of viable samples. Given there are multiple required samples, bone marrow acquisition techniques such as frequent repositioning or performing bilateral bone marrow testing should be considered to avoid insufficient material for required studies. Consider a repeat marrow prior to starting treatment if there is insufficient diagnostic material for the required studies Patients must be less than 22 years of age at the time of study enrollment Patient must be newly diagnosed with de novo AML according to the 2016 World Health Organization (WHO) classification with or without extramedullary disease Patient must have 1 of the following >= 20% bone marrow blasts (obtained within 14 days prior to enrollment) In cases where extensive fibrosis may result in a dry tap, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core biopsy < 20% bone marrow blasts with one or more of the genetic abnormalities (sample obtained within 14 days prior to enrollment) A complete blood count (CBC) documenting the presence of at least 1,000/uL (i.e., a white blood cell [WBC] count >= 10,000/uL with >= 10% blasts or a WBC count of >= 5,000/uL with >= 20% blasts) circulating leukemic cells (blasts) if a bone marrow aspirate or biopsy cannot be performed (performed within 7 days prior to enrollment) ARM C: Patient must be >= 2 years of age at the time of Late Callback ARM C: Patient must have FLT3/ITD allelic ratio > 0.1 as reported by Molecular Oncology  Patients with myeloid neoplasms with germline predisposition are not eligible Fanconi anemia Shwachman Diamond syndrome Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 Any other known bone marrow failure syndrome Any concurrent malignancy Juvenile myelomonocytic leukemia (JMML) Philadelphia chromosome positive AML Mixed phenotype acute leukemia Acute promyelocytic leukemia
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB Triple negative breast cancer / HER2-positive breast cancer (ER / PR +/-) age> 18 years morphologically confirmed diagnosis of breast cancer, IIA-IIIA stage ECOG score 0-1 life expectancy of more than 3 months the consent of patients to use reliable methods of contraception throughout the study adequate liver and bone marrow function the absence of contraindications to surgical intervention (including anesthetic risk is taken into account)  Inconsistency with criteria Conducting earlier any systemic therapy for breast cancer stage 4 cancer carrier mutations of the BRCA1 / 2 gene severe uncontrolled concomitant chronic diseases or acute diseases the presence of a second malignant tumor pregnancy or lactation acute conditions and complications, which, according to the doctor, interfere with treatment